Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The rationale for this multicenter, phase II trial is to examine the impact of
carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage
IB (> 4.0 cm), II, and select stage III NSCLC. If this novel regimen proves to be safe and
active in this setting, this would provide rationale for further investigation in a larger,
prospective, randomized setting.